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Abstract We have previously demonstrated that muscarinic and 
cu-adrenergic receptors regulated a phospholipase D (PLD) activ- 
ity in parotid glands. Since phorbol lZmyristate, 13-acetate 
(PMA) induced production of phosphatidylethanol (PEt), a stable 
metabolite widely accepted as marker of PLD activation, we have 
investigated the role of protein kinase C (PKC) in PLD stimula- 
tion in parotid acini. We tested PKC inhibitors on PEt formation 
elicited by PMA, by muscarinic and adrenergic agents. Stauro- 
sporine and chelerythrine, which act on the catalytic domain of 
PKC, did not allow the attribution of a role for PKC in PLD 
activation. Indeed, staurosporine did not affect PMA-mediated 
PLD activity and chelerythrine showed an important non-specific 
effect, independent of PKC inhibition. On the other hand, cal- 
phostin C, which acts on the regulatory domain of PKC, affected 
PMA- and receptor-mediated PLD stimulation. We attributed 
this effect to PKC inhibition and we suggested PKC involvement 
in PLD regulation in parotid gland. Since only PKC inhibitor 
acting on the regulatory part of the enzyme affected PLD activ- 
ity, we also suggested that PKC could be involved in PLD activa- 
tion through a pathway independent of the phosphorylation mech- 
anism. 
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1. Introduction 
Phospholipase D (PLD) catalyzes the hydrolysis of the termi- 
nal phosphodiester bond of phospholipids to yield the appro- 
priate free polar head group and phosphatidic acid (PA), a 
potential lipid second messenger [l-3]. PA is also formed by 
either de novo synthesis or by the combined actions of phos- 
pholipase C (PLC) and diacylglycerol kinase. Phosphati- 
dylcholine, mainly, but also phosphatidylinositol and 
phosphatidylethanolamine have been reported as substrates for 
PLD in different mammalian tissues [47]. In addition, PLD 
possesses the unique ability to catalyze a transphosphatidyla- 
tion reaction in which the phosphatidyl moiety of phospholip- 
ids is transferred to a primary alcohol such as ethanol, thereby 
resulting in the formation of a phosphatidylalcohol such as 
phosphatidylethanol (PEt) [8]. Although PLD activation has 
been described in many cells, the mechanisms involved in the 
regulation of PLD activity still remain unclear. 
Taking advantage of the unique ability of PLD to catalyze 
the transphosphatidylation reaction, we have recently demon- 
strated the presence of PLD and its regulation by muscarinic 
and a-adrenergic receptors in the rat parotid gland, an exocrine 
gland [9,10]. Indeed, we have reported that stimulation of these 
receptors induced labelled PEt production in [3H]myristic acid- 
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or [14C]stearic acid-labelled parotid acini. Phorbol esters, acti- 
vators of protein kinase C (PKC), and a calcium ionophore also 
caused PEt formation [lo]. Furthermore, the production of 
labelled PA in the parotid glands during stimulation of muscar- 
inic and a-adrenergic receptors was attributed to the combined 
actions of PLC and diacylglycerol kinase [lo]. A relationship 
between the activation of phospholipases C and D may be 
possible in parotid acini. 
The present work was undertaken in order to elucidate the 
role of PKC in the regulation of PLD activity in the rat parotid 
gland. For this, we tested PKC inhibitors on the formation of 
labelled PEt elicited in response to phorbol ester, to muscarinic 
and a adrenergic agonists. Three inhibitors were used: stauro- 
sporine and chelerythrine which act on the catalytic part of 
PKC, affecting the binding of either ATP or proteinic sub- 
strates on PKC and calphostin C which acts on the regulatory 
part of PKC. We found evidence for PKC involvement in PLD 
regulation, since calphostin C prevented labelled PEt produc- 
tion. However, staurosporine and chelerythrine were without 
significant inhibitory effect. Since only the PKC inhibitor act- 
ing on the regulatory part of the enzyme affected PLD activity, 
we suggested that PKC could be involved in PLD regulation 
in the parotid gland, through a pathway independent of the 
phosphorylation mechanism. 
2. Materials and methods 
2.1. Materials 
Male albino Sprague-Dawley rats, 6-7 weeks old were used in this 
study. 
[I-“‘C]Stearic acid (2.1 GBq/mmol; 58 mCi/mmol) was purchased 
from Du Pont de Nemours/New England Nuclear division. France. 
Collagenase type CLS III Worthington (116 U/mg) was from Seromed, 
Germany. Bovine serum albumin (fatty acid-free BSA), 4/I-phorbol 
12-myristate 13-acetate (PMA) and epinephrine were obtained from 
Sigma Chemical Co., St. Louis, MO. Phosphatidylethanol standard 
was purchased from Avanti Polar Lipids Inc., Birmingham, AL. Car- 
bamylcholine was from Merck, Darmstadt, Germany. Precoated silica 
gel plates were purchased from J.T. Baker Inc., France, and solvents 
were from Prolabo. All reagents were of the highest purity available. 
2.2. Methods 
2.2.1. Preparation of parotid acini, radiolabelling and treat- 
ments. Rats were killed by CO, inhalation. Parotid glands were rap- 
idly removed, trimmed of their fatty and connective tissues and frag- 
mented into small pieces. Parotid gland pieces were washed with buffer 
(Krebs-Ringer bicarbonate buffer supplemented with 0.55 mM glu- 
cose, 10 mM HEPES and 0.1% BSA, pH 7.4) at 37°C. Tissue was 
incubated in this buffer plus collagenase (116 U/ml) for 30 min at 37” C 
under a stream of O,/CO, (95%/5%). Parotid acini were dissociated by 
successive pipetting through pipette tips of decreasing diameters. At the 
end of this dissociation period, the preparation was filtered through 
nylon mesh (120 pm pore size). Filtrate was centrifuged for 5 min at 
50 x g to eliminate medium and collagenase. The pellet was resus- 
pended in buffer and washed by centrifugation through a solution of 
4% BSA in the same buffer (at 50 x g, for 5 min). The resulting pellet, 
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by centrifugation at 50 x g, for 5 min. Parotid acini were resuspended 
in buffer and aliquoted in 1 ml of incubation medium. 
Ethanol was added to the incubation medium to obtain a final con- 
centration of 2% (340 mM). Acini were preincubated for 5 min and then 
reaction was started by addition of stimuli. The final concentration of 
dimethyl sulfoxide in which PMA was initially dissolved did not exceed 
0.1% in the assay, a concentration that had no discernible effect on the 
parameters measured. The reaction was stopped by adding chloroform/ 
methanoVHC1 12 N (100:200: 1 by volume). 
2.2.2. Lipid analysis. Total cellular lipids were extracted according 
to the method of Bligh and Dyer [l 11. The lower chloroform phase was 
dried and spotted on silica gel plates. The plates were developed using 
the upper phase of a mixture consisting of ethylacetate/trimethylpen- 
tane/acetic acid/water (130 : 20 : 30 : 100 by volume), as described previ- 
ously [lo]. The silica gels were analysed with a TLC linear analyser 
(Berthold) for at least 1 h, to have a good estimation of the radioactiv- 
ity. The background of the thin layer chromatography plate was deter- 
mined and subtracted from each experimental sample. Lipids were 
located by staining with iodine vapor and identified by comparison with 
standard lipids. 
The amount of [“‘Clphosphatidylethanol and [?]phosphatidic acid 
produced was determined as a percentage of the total radioactivity 
(about 30,000 cpm). The basal value was substracted from the stimu- 
lated value to determine a net production of PEt or PA. Assays were 
done in duplicate. Each experiment was performed 2 times. Data ob- 
tained from a representative experiment were presented as the mean 
with the range for the duplicate samples. 
3. Results and discussion 
Staurosporine is an inhibitor of PKC which interferes with 
the binding of ATP on the catalytic domain of the enzyme 
[ 12,131. This feature of staurosporine appears to be responsible 
for its lack of selectivity for PKC over several other kinases. We 
tested staurosporine at 0.1 ,uM and 1 PM on the [14C]PEt pro- 
duction induced by the phorbol ester, PMA, in the parotid 
acini. We found that this response was not significantly affected 
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Fig. 1. Effect of staurosporine on the formation of [14C]PEt. [14C]Stearic 
acid-labelled-parotid acini were preincubated for 10 min in the presence 
or in the absence of staurosporine and then stimulated or not for 20 min 
with PMA (1 PM). [14C]PEt production was determined as described 
in section 2. Data were expressed as the percentage of the control, i.e. 
the net [14C]PEt production induced in parotid acini stimulated with 
PMA in the absence of staurosporine (0.026% + 0.001). 
which was the final parotid acinar preparation, was resuspended in 
buffer. 
[14C]Stearic acid was dissolved in buffer by vigorous vortexing and 
sonification. Parotid acini were incubated for 3 h in 5 ml of buffer 
supplemented with [14C]stearic acid (lO,Ki/ml) at 37”C, under a stream 
of O,/CO,. Radioactivity in the incubation medium was then eliminated 
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Fig. 2. Effect of chelerythrine on the formation of [14C]PEt and of [‘4C]PA. [‘4C]Stearic acid-labelled-parotid acini were preincubated for 10 min in 
the presence or in the absence of chelerythrine and then stimulated or not for 20 min with PMA (1 PM) (A) or carbamylcholine (1 mM) (B,C). [14C]PEt 
(A,B) and [14C]PA (C) productions were determined as described in section 2. Data were expressed as the percentage of the control, i.e. the net [14C]PEt 
or [14C]PA production induced in parotid acini stimulated in the absence of chelerythrine (1 PM PMA: [14C]PEt = 0.060% + 0.001; 1 mM CCH: 
[14C]PEt = 0.058% f 0.008, [14C]PA = 0.376% f 0.059). 
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Fig. 3. Effect of calphostin C on the formation of [?]PEt and of [‘TIPA. [‘4C]stearic acid-labelled-parotid acini were preincubated for 10 min in 
the presence or in the absence of calphostin C and then stimulated or not for 20 min with PMA (1 ,uM or 0.1 ,uM) (A,B) or carbamylcholine (1 mM 
or 0.1 mM) (C,D,E,F). [‘T]PEt (A,B,C,D) and [“‘CIPA (E,F) productions were determined as described in section 2. Data were expressed as the 
percentage of the control, i.e. the net [?Z]PEt or [“‘CIPA production induced in parotid acini stimulated in the absence of calphostin C (1 PM PMA: 
[14C]PEt = 0.023% k 0.003; 0.1 ,uM PMA: [W]PEt = 0.019% f 0.001; 1 mM CCH: [‘T]PEt = 0.025% f 0.003, [14C]PA = 0.106% f 0.010; 0.1 mM 
CCH: [W]PEt = 0.020% f 0.001, [?Z]PA = 0.079% f 0.005). N.D.: not determined. 
by staurosporine (0.1 and 1 ,uM) treatment (Fig. 1). However, 
it should be noted that 1 yM staurosporine alone induced a 
weak [14C]PEt formation (0.028% f 0.002 vs. 0.021% ? 0.001 in 
non-treated samples). This result seems in agreement with other 
previous data indicating that staurosporine had different non- 
specific effects, independent of PKC inhibition [13]. In particu- 
lar, it has been reported that staurosporine blocked PKC acti- 
vation and independently induced PLD stimulation in human 
PMNs [ 141. Thus, whereas 0.1 PM staurosporine did not affect 
PLD activity, used at 1 PM, it could itself weakly enhance this 
activity in parotid gland. 
Chelerythrine interacts with the catalytic domain of PKC 
and is a competitive inhibitor with respect to the proteinic 
substrates of the kinase [15]. At 10 ,uM, chelerythrine did not 
affect significantly the [14C]PEt production induced by PMA or 
by carbamylcholine (CCH), the muscarinic cholinergic agonist 
(Fig. 2A,B). On the other hand, preincubation of the parotid 
acini with chelerythrine at 100 PM completely inhibited these 
responses (Fig. 2A,B). However, the inhibition of these re- 
sponses obtained with 100 ,uM chelerythrine could result from 
a non-specific effect of the PKC inhibitor rather than PKC 
inhibition itself. Indeed, 100 ,uM chelerythrine also completely 
inhibited the production of [14C]PA stimulated by CCH (Fig. 
2C). It is therefore likely that chelerythrine at 100 ,uM affected 
both phospholipase C and D activities, whereas when used at 
10 ,uM it failed to affect all of them in the parotid gland. 
Considering our results, we have previously suggested that PLC 
activation was required for PLD activation by carbamylcholine 
[lo]. In this case, non-specific inhibition of PLC would result 
in PLD inhibition and thus, chelerythrine did not provide evi- 
dence for a role of PKC in PLD regulation in the parotid gland. 
Calphostin C is a potent and specific inhibitor of PKC which 
interacts with the regulatory domain of the kinase [16]. This 
compound showed inhibitory effects by competing at the bind- 
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ing site for diacylglycerol and phorbol esters [ 161. In a first time, 
we tested calphostin C at different concentrations on the 
[14C]PEt production elicited by PMA at maximal (1 ,uM) and 
submaximal (0.1 PM) concentrations. Fig. 3A,B showed that 
preincubation of parotid acini in the presence of calphostin C 
affected PLD activation by PMA. Calphostin C induced a 
concentration-dependent decrease of the control value (PMA 
stimulation without calphostin C treatment). However, a more 
important calphostin C effect was observed on the PLD activa- 
tion obtained with PMA at a submaximal concentration (Fig. 
3B). Indeed, a complete inhibition of the [14C]PEt production 
was observed with 1 ,uM calphostin C, when parotid acini were 
stimulated with 0.1 ,uM PMA (Fig. 3B), while inhibition 
reached only 75%, when acini were stimulated with 1 ,uM PMA 
(Fig. 3A). These results could be interpreted as being a compet- 
itive inhibition by calphostin C of the PMA-induced PLD acti- 
vation. Fig. 3C,D represents the effect of calphostin C at differ- 
ent concentrations on the [14C]PEt production in parotid acini 
stimulated by CCH (1 mM or 0.1 mM). While we did not find 
any important effect on this response induced by 1 mM CCH 
(Fig. 3C), we observed a significant inhibition of calphostin C 
on the one induced by 0.1 mM CCH (Fig. 3D). This inhibition 
was observed at all the calphostin C concentrations tested and 
reached 95%. It should be observed that calphostin C at 0.5 and 
1 ,uM affected also the [14C]PA production induced by CCH 
(0.1 mM) (Fig. 3F). However, this effect on the PA level was 
very lower (35%) than the one related to the PEt level. Taking 
together these data obtained with calphostin C, it appears that 
PLD activation by phorbol ester and muscarinic receptor ag- 
onist would be mediated through PKC dependent processes. A 
similar conclusion was found for PLD activation by an 01 
adrenergic agonist, epinephrine. Indeed, [14C]PEt production 
induced by 10 FM epinephrine in parotid acini preincubated in 
the presence of 1 ,uM calphostin C represented only 7% of the 
response observed in acini non-treated with the PKC inhibitor 
(data not shown). 
While the effects observed with calphostin C on PLD activa- 
tion in parotid gland indicated a PKC involvement, the ones 
observed with chelerythrine and staurosporine led to conflict- 
ing conclusion. These contrasting data could be explained by 
the different targets of the different PKC inhibitors used. In- 
deed, PLD inhibition was obtained in parotid acini treated only 
with PKC inhibitor acting on the regulatory domain of the 
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enzyme. It is possible that phosphorylation by PKC was not 
required to PLD activation even if PKC dependent processes 
mediated PLD activation. A similar conclusion has been previ- 
ously reported by Conricode et al. [17]. These authors demon- 
strated that PMA stimulated PLD in fibroblast membranes 
supplemented with PKC, but did not need exogenous ATP. 
They concluded the involvement of PKC in the activation of 
PLD and suggested that ATP-dependent phosphorylation was 
not required [17]. Our data suggest that such a pathway of PLD 
activation could be involved in a cellular system. 
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